We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Arcutis Biotherapeutics Inc | NASDAQ:ARQT | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.59 | -6.86% | 8.01 | 8.01 | 13.00 | 9.0959 | 7.97 | 8.79 | 2,596,520 | 05:00:05 |
Details for the presentation are as follows: |
Goldman Sachs 41st Annual Global Healthcare Conference WebcastPresentation Date: Thursday, June 11, 2020Presentation Time: 11:10 a.m. PT / 2:10 p.m. ET |
The presentation will be webcast and may be accessed at the “Events & Presentations” section of the Company’s website at https://investors.arcutis.com/events-and-presentations. Arcutis will maintain an archived replay of the webcast on its website for 30 days after the conference.
About Arcutis - Bioscience, applied to the skin.Arcutis is a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. Arcutis exploits recent innovations in inflammation and immunology to develop potential best-in-class therapies against validated biological targets, leveraging our deep development, formulation and commercialization expertise to bring to market novel dermatology treatments, while maximizing our probability of technical success and financial resources. Arcutis is currently developing four novel compounds, including ARQ-151 (topical roflumilast cream); ARQ-154 (topical roflumilast foam); ARQ-252, and ARQ-255 for multiple indications, including psoriasis, atopic dermatitis, seborrheic dermatitis, and eczema, vitiligo, and alopecia areata. For more information, please visit www.arcutis.com or follow the Company on LinkedIn.
Investors and Media:Heather Rowe ArmstrongVice President, Investor Relations & Corporate Communicationsharmstrong@arcutis.com805-418-5006, Ext. 740
1 Year Arcutis Biotherapeutics Chart |
1 Month Arcutis Biotherapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions